Marked Increased Production of Acute Phase Reactants by Skeletal Muscle during Cancer Cachexia.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

acute phase reactants; cachexia; cancer; proteomics; secretome; skeletal muscle

Abstract :

[en] Loss of skeletal muscle mass in cancer cachexia is recognized as a predictor of mortality. This study aimed to characterize the changes in the muscle secretome associated with cancer cachexia to gain a better understanding of the mechanisms involved and to identify secreted proteins which may reflect this wasting process. The changes in the muscle proteome of the C26 model were investigated by label-free proteomic analysis followed by a bioinformatic analysis in order to identify potentially secreted proteins. Multiple reaction monitoring and Western blotting were used to verify the presence of candidate proteins in the circulation. Our results revealed a marked increased muscular production of several acute phase reactants (APR: Haptoglobin, Serine protease inhibitor A3N, Complement C3, Serum amyloid A-1 protein) which are released in the circulation during C26 cancer cachexia. This was confirmed in other models of cancer cachexia as well as in cancer patients. Glucocorticoids and proinflammatory cytokines are responsible for an increased production of APR by muscle cells. Finally, their muscular expressions are strongly positively correlated with body weight loss as well as the muscular induction of atrogens. Our study demonstrates therefore a marked increased production of APR by the muscle in cancer cachexia.

Disciplines :

Gastroenterology & hepatology

Author, co-author :

Massart, Isabelle S.

PAULISSEN, Geneviève ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de rhumatologie

Loumaye, Audrey

Lause, Pascale

Pötgens, Sarah A.

Thibaut, Morgane M.

Balan, Estelle

Deldicque, Louise

Atfi, Azeddine

Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie

More authors (4 more)

Language :

English

Title :

Marked Increased Production of Acute Phase Reactants by Skeletal Muscle during Cancer Cachexia.

Publication date :

2020

Journal title :

Cancers

eISSN :

2072-6694

Publisher :

Multidisciplinary Digital Publishing Institute (MDPI), Switzerland

Volume :

Issue :

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

http://www.mdpi.com/journal/cancers

Name of the research project :

Télévie grant 7.4533.16, 7.4564.17 et 7.4503.18; grant NIH R01CA210911, R01-AR05071 et R01CA240484; Département de la Défense PF162051

Funders :

Télévie [BE]
Centre Hospitalier Universitaire de Liège - CHU Liège hépato-gastroentérologie et oncologie digestive
Ministère de la Défense (Belgique)
NIH - National Institutes of Health [US-MD]
FRIA - Fonds pour la Formation à la Recherche dans l'Industrie et dans l'Agriculture [BE]

Available on ORBi :

since 06 January 2021

Statistics

Number of views

58 (4 by ULiège)

Number of downloads

49 (2 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Argiles, J.M.; Busquets, S.; Stemmler, B.; Lopez-Soriano, F.J. Cancer cachexia: Understanding the molecular basis. Nat. Rev. Cancer 2014, 14, 754–762, doi:10.1038/nrc3829.
Fonseca, G.W.P.D.; Farkas, J.; Dora, E.; von Haehling, S.; Lainscak, M. Cancer Cachexia and Related Metabolic Dysfunction. Int. J. Mol. Sci. 2020. 21, doi:10.3390/ijms21072321.
Schiessel, D.L.; Baracos,V.E. Barriers to cancer nutrition therapy: Excess catabolism of muscle and adipose tissues induced by tumour products and chemotherapy. Proc. Nutr. Soc. 2018, 77, 394–402, doi:10.1017/S0029665118000186.
Fearon, K. F.; Strasser, S.D.; Anker, I.; Bosaeus, E.; Bruera, R.L. Fainsinger, et al. Definition and classification of cancer cachexia: An international consensus. Lancet Oncol. 2011, 12, 489–495, doi:10.1016/s1470-2045(10)70218-7.
Fearon, K.C., Glass, D.J.; Guttridge, D.C. Cancer cachexia: Mediators, signaling, and metabolic pathways. Cell Metab. 2012, 16, 153–166, doi:10.1016/j.cmet.2012.06.011.
Klimek, M.E.B.; Aydogdu, T.; Link, M.J.; Pons, M.; Koniaris, L.G.; Zimmers, T.A. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem. Biophys. Res. Commun. 2010, 391, 1548–1554, doi:10.1016/j.bbrc.2009.12.123.
Zhou, X.; Wang, J.L.; Lu, Y.; Song, K.S.; Kwak, K.S.; Jiao, Q.; et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 2010, 142, 531–543, doi:10.1016/j.cell.2010.07.011.
Pedersen, B.K. Muscle as a secretory organ. Compr. Physiol. 2013, 3, 1337–1362, doi:10.1002/cphy.c120033.
Whitham, M.; Febbraio, M.A. The ever-expanding myokinome: Discovery challenges and therapeutic implications. Nat. Rev. Drug Discov. 2016, 15, 719–729, doi:10.1038/nrd.2016.153.
Bodine, S.C.; Baehr, L.M. Skeletal muscle atrophy and the E3 ubiquitin ligases MuRF1 and MAFbx/atrogin-1. Am. J. Physiol. Endocrinol Metab. 2014, 307, E469–E484, doi:10.1152/ajpendo.00204.2014.
Acharyya, S.; Ladner, K.J.; Nelsen, L.L.; Damrauer, J.; Reiser, P.J.; Swoap, S.; et al. Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J. Clin. Invest. 2004, 114, 370–380, doi:10.1172/jci20174.
Bonetto, A.; Rupert, J.E.; Barreto, R.; Zimmers,T.A. The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia. J. Vis. Exp. 2016, doi:10.3791/54893.
Bertaggia, E.; Scabia, G.; Dalise, S.; Lo Verso, F.; Santini, F.; Vitti, P.; et al. Haptoglobin is required to prevent oxidative stress and muscle atrophy. PLoS ONE 2014. 9, e100745, doi:10.1371/journal.pone.0100745.
Passey, S.L.; Bozinovski; S.; Vlahos, R.; Anderson, G.P.; Hansen, M.J. Serum Amyloid A Induces Toll-Like Receptor 2-Dependent Inflammatory Cytokine Expression and Atrophy in C2C12 Skeletal Muscle Myotubes. PLoS ONE 2016. 11, e0146882, doi:10.1371/journal.pone.0146882.
Zhang, L.; Du, J.; Hu, Z.; Han, G.; Delafontaine, P.; Garcia, G.; et al. IL-6 and serum amyloid A synergy mediates angiotensin II-induced muscle wasting. J. Am. Soc. Nephrol. 2009, 20, 604–612, doi:10.1681/asn.2008060628.
Zhang, X.; Chen, J.; Wang,S. Serum Amyloid A Induces a Vascular Smooth Muscle Cell Phenotype Switch through the p38 MAPK Signaling Pathway. BioMed Res. Int. 2017, 2017, 4941379, doi:10.1155/2017/4941379.
Tjondrokoesoemo, A.; Schips, T.; Kanisicak, O.; Sargent, M.A.; Molkentin. J.D. Genetic overexpression of Serpina3n attenuates muscular dystrophy in mice. Hum. Mol. Genet. 2016, 25, 1192–1202, doi:10.1093/hmg/ddw005.
Remy, K.E.; Cortes-Puch, I.; Solomon, S.B.; Sun, J.; Pockros, B.M.; Feng, J.; et al. Haptoglobin improves shock, lung injury, and survival in canine pneumonia. JCI Insight 2018, 3, doi:10.1172/jci.insight.123013.
Parajuli, P.; Kumar, S.; Loumaye, A.; Singh, P.; Eragamreddy, S.; Nguyen, T.L.; et al. Twist1 Activation in Muscle Progenitor Cells Causes Muscle Loss Akin to Cancer Cachexia. Dev. Cell 2018, 45, 712–725.e6, doi:10.1016/j.devcel.2018.05.026.
Bindels, L.B.; Beck, R.; Schakman, O.; Martin, J.C.; De Backer, F.; Sohet,F.M.; et al. Restoring specific lactobacilli levels decreases inflammation and muscle atrophy markers in an acute leukemia mouse model. PLoS ONE 2012, 7, e37971, doi:10.1371/journal.pone.0037971.
Bindels, L.B.; Neyrinck, A.M.; Loumaye, A.; Catry, E.; Walgrave, H.; Cherbuy, C.; et al., Increased gut permeability in cancer cachexia: Mechanisms and clinical relevance. Oncotarget 2018. 9, 18224–18238, doi:10.18632/oncotarget.24804.
Bode, J.G.; Albrecht, U.; Haussinger, D.; Heinrich, P.C.; Schaper, F. Hepatic acute phase proteins--regulation by IL-6-and IL-1-type cytokines involving STAT3 and its crosstalk with NF-kappaB-dependent signaling. Eur J. Cell Biol. 2012, 91, P. 496–505, doi:10.1016/j.ejcb.2011.09.008.
Narsale, A.A. and J.A.; Carson, Role of interleukin-6 in cachexia: Therapeutic implications. Curr. Opin. Supportive Palliat. Care 2014, 8, 321–327, doi:10.1097/SPC.0000000000000091.
Gabay, C.; Kushner, I. Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med. 1999, 340, 448–454, doi:10.1056/nejm199902113400607.
Shum, A.M.; Fung, D.C.; Corley, S.M.; McGill, M.C.; Bentley, N.L.; Tan, T.C.; et al. Cardiac and skeletal muscles show molecularly distinct responses to cancer cachexia. Physiol Genom. 2015, 47, 588–599, doi:10.1152/physiolgenomics.00128.2014.
Bonetto, A.; Aydogdu, T.; Kunzevitzky, N.; Guttridge, D.C.; Khuri. S.; Koniaris, L.G.; et al., STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia. PLoS ONE 2011, 6, e22538, doi:10.1371/journal.pone.0022538.
Cornwell, E.W.; Mirbod, A.; Wu, C.L.; Kandarian, S.C.; Jackman, R.W. C26 cancer-induced muscle wasting is IKKbeta-dependent and NF-kappaB-independent. PLoS ONE 2014, 9, e87776, doi:10.1371/journal.pone.0087776.
Judge, S.M.; Wu, C.L.; Beharry, A.W.; Roberts, B.M.; Ferreira, L.F.; Kandarian, S.C.; et al. Genome-wide identification of FoxO-dependent gene networks in skeletal muscle during C26 cancer cachexia. BMC Cancer 2014, 14, 997, doi:10.1186/1471-2407-14-997.
Talbert, E.E., M.C.; Cuitino, K.J.; Ladner, P.V.; Rajasekerea, M.; Siebert, R. Shakya, et al., Modeling Human Cancer-induced Cachexia. Cell Rep. 2019, 28, 1612–1622.e4, doi:10.1016/j.celrep.2019.07.016.
Barreto, R.; Mandili, G.; Witzmann, F.A.; Novelli, F.; Zimmers, T.A.; Bonetto, A. Cancer and Chemotherapy Contribute to Muscle Loss by Activating Common Signaling Pathways. Front. Physiol. 2016, 7, 472, doi:10.3389/fphys.2016.00472.
Braun, T.P., A.J.; Grossberg, S.M.; Krasnow, P.R.; Levasseur, M.; Szumowski, X.X. Zhu, et al., Cancer-and endotoxin-induced cachexia require intact glucocorticoid signaling in skeletal muscle. Faseb J. 2013, 27, 3572–3582, doi:10.1096/fj.13-230375.
Rosa-Caldwell, M.E.; Fix, D.K.; Washington, T.A.; Greene, N.P. Muscle alterations in the development and progression of cancer-induced muscle atrophy: A review. J. Appl Physiol, 2020. 128, 25–41, doi:10.1152/japplphysiol.00622.2019.
Argilés, J.M.; López-Soriano, F.J.; Busquets, S. Mediators of cachexia in cancer patients. Nutrition. 2019, 66, 11–15, doi:10.1016/j.nut.2019.03.012.
Murphy, S.; Dowling, P.; Zweyer, M.; Henry, M.; Meleady, P.; Mundegar, R.R.; et al. Proteomic profiling of mdx-4cv serum reveals highly elevated levels of the inflammation-induced plasma marker haptoglobin in muscular dystrophy. Int. J. Mol. Med. 2017, 39, 1357–1370, doi:10.3892/ijmm.2017.2952.
Gueugneau, M.; d’Hose, D.; Barbe, C.; de Barsy, M.; Lause, P.; Maiter, D.; et al. Increased Serpina3n release into circulation during glucocorticoid-mediated muscle atrophy. J. Cachexia Sarcopenia Muscle. 2018, 9, 929– 946, doi:10.1002/jcsm.12315.
Langhans, C.; Weber-Carstens, S.; Schmidt, F.; Hamati, J.; Kny, M.; Zhu, X.; et al. Inflammation-induced acute phase response in skeletal muscle and critical illness myopathy. PLoS ONE 2014, 9, e92048, doi:10.1371/journal.pone.0092048.
Ebhardt, H.A.; Degen, S.; Tadini, V.; Schilb, A.; Johns, N.; Greig, C.A.; et al. Comprehensive proteome analysis of human skeletal muscle in cachexia and sarcopenia: A pilot study. J. Cachexia Sarcopenia Muscle 2017, 8, 567–582, doi:10.1002/jcsm.12188.
Hahn, A.; Kny, M.; Pablo-Tortola, C.; Todiras, M.; Willenbrock, M.; Schmidt, S.; et al. Serum amyloid A1 mediates myotube atrophy via Toll-like receptors. J. Cachexia Sarcopenia Muscle 2019, doi:10.1002/jcsm.12491.
Zhang, C.; Wang, C.; Li, Y.; Miwa, T.; Liu, C.; Cui, W.; et al. Complement C3a signaling facilitates skeletal muscle regeneration by regulating monocyte function and trafficking. Nat. Commun. 2017, 8, 2078–2078, doi:10.1038/s41467-017-01526-z.
Lautaoja, J.H.; Lalowski, M.; Nissinen, T.A.; Hentila,J.; Shi, Y.; Ritvos, O.; et al. Muscle and serum metabolomes are dysregulated in colon-26 tumor-bearing mice despite amelioration of cachexia with activin receptor type 2B ligand blockade. Am. J. Physiol. Endocrinol. Metab. 2019, 316, E852–E865, doi:10.1152/ajpendo.00526.2018.
Neyroud, D.; Nosacka, R.L.; Judge, A.R.; Hepple, R.T. Colon 26 adenocarcinoma (C26)-induced cancer cachexia impairs skeletal muscle mitochondrial function and content. J. Muscle Res. Cell Motil. 2019, 40, 59– 65, doi:10.1007/s10974-019-09510-4.
Shum, A.M.; Mahendradatta, T.; Taylor, R.J.; Painter, A.B.; Moore, M.M.; Tsoli, M.; et al. Disruption of MEF2C signaling and loss of sarcomeric and mitochondrial integrity in cancer-induced skeletal muscle wasting. Aging, 2012, 4, 133–143, doi:10.18632/aging.100436.
Ballarò, R.; Beltrà, M.; Lucia, S.D.; Pin, F.; Ranjbar, K.; Hulmi, J.J.; et al. Moderate exercise in mice improves cancer plus chemotherapy-induced muscle wasting and mitochondrial alterations. FASEB J. 2019, 33, 5482– 5494, doi:10.1096/fj.201801862R.
Pin, F.; Barretol R.; Couch, M.E.; Bonetto, A.; O’Connell, T.M. Cachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolism. J. Cachexia Sarcopenia Muscle 2019, 10, 140–154, doi:10.1002/jcsm.12360.
Brown, J.L.; Rosa-Caldwell, M.E.; Lee, D.E.; Blackwell, T.A.; Brown, L.A.; Perry, R.A.; et al. Mitochondrial degeneration precedes the development of muscle atrophy in progression of cancer cachexia in tumour-bearing mice. J. Cachexia Sarcopenia Muscle 2017, 8, 926–938, doi:10.1002/jcsm.12232.
de Castro, G.S.; Simoes, E.; Lima, J.; Ortiz-Silva, M.; Festuccia, W.T.; Tokeshi, F.; et al. Human Cachexia Induces Changes in Mitochondria, Autophagy and Apoptosis in the Skeletal Muscle. Cancers, 2019, 11, doi:10.3390/cancers11091264.
Nissinen, T.A.; Hentila, J.; Penna, F.; Lampinen, A.; Lautaoja, J.H.; Fachada, V.; et al. Treating cachexia using soluble ACVR2B improves survival, alters mTOR localization, and attenuates liver and spleen responses. J. Cachexia Sarcopenia Muscle 2018, 9, 514–529, doi:10.1002/jcsm.12310.
Deshmukh, A.S.; Murgia, M.; Nagaraj, N.; Treebak, J.T.; Cox, J.; Mann, M. Deep proteomics of mouse skeletal muscle enables quantitation of protein isoforms, metabolic pathways, and transcription factors. Mol. Cell Proteom. 2015, 14, 841–853, doi:10.1074/mcp.M114.044222.
Shum, A.M.Y.; Poljak, A.; Bentley, N.L.; Turner, N.; Tan, T.C.; Polly, P. Proteomic profiling of skeletal and cardiac muscle in cancer cachexia: Alterations in sarcomeric and mitochondrial protein expression. Oncotarget 2018, 9, 22001–22022, doi:10.18632/oncotarget.25146.
Sciorati, C.; Touvier, T.; Buono, R.; Pessina, P.; François, S.; Perrotta, C.; et al. Necdin is expressed in cachectic skeletal muscle to protect fibers from tumor-induced wasting. J. Cell Sci. 2009, 122, 1119–1125, doi:10.1242/jcs.041665.
Pierre, N.; Salée C.; Massot, C.; Blétard, N.; Mazzucchelli, G.; Smargiasso, N.; et al.; Proteomics Highlights Common and Distinct Pathophysiological Processes Associated with Ileal and Colonic Ulcers in Crohn’s Disease. J. Crohns Colitis 2020, 14, 205–215, doi:10.1093/ecco-jcc/jjz130.
Tyanova, S.; Temu, T.; Cox, J. The MaxQuant computational platform for mass spectrometry-based shotgun proteomics. Nat. Protoc. 2016, 11, 2301–2319, doi:10.1038/nprot.2016.136.
Cox, J.; Hein, M.Y.; Luber, C.A.; Paron, I.; Nagaraj, N.; Mann, M. Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. Mol. Cell Proteom. 2014, 13, 2513–2526, doi:10.1074/mcp.M113.031591.
Perez-Riverol, Y.; Csordas, A.; Bai, J.; Bernal-Llinares, M.; Hewapathirana, S.; Kundu, D.J.; et al. The PRIDE database and related tools and resources in 2019: Improving support for quantification data. Nucleic Acids Res. 2019, 47, D442–D450, doi:10.1093/nar/gky1106.
Tyanova, S.; Temu, T.; Sinitcyn, P.; Carlson, A.; Hein, M.Y.; Geiger, T.; et al. The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat. Methods 2016, 13, 731–740, doi:10.1038/nmeth.3901.
MacLean, B.; Tomazela, D.M.; Shulman, N.; Chambers, M.; Finney, G.L.; Frewen, B.; et al. Skyline: An open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 2010, 26, 966–968, doi:10.1093/bioinformatics/btq054.
Loumaye, A.; de Barsy, M.; Nachit, M.; Lause, P.; Frateur, L.; van Maanen, A.; et al. Role of Activin A and myostatin in human cancer cachexia. J. Clin. Endocrinol. Metab. 2015, 100, 2030–2080, doi:10.1210/jc.2014-4318.
Balan, E.; Schwalm, C.; Naslain, D.; Nielens, H.; Francaux, M.; Deldicque, L. Regular Endurance Exercise Promotes Fission, Mitophagy, and Oxidative Phosphorylation in Human Skeletal Muscle Independently of Age. Front. Physiol. 2019, 10, 1088, doi:10.3389/fphys.2019.01088.